Utilizing Nanobody Technology to Target Non-Immunodominant Domains of VAR2CSA
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Placental malaria is a major health problem for both pregnant women and their fetuses in malaria endemic regions. It is triggered by the accumulation of Plasmodium falciparum-infected erythrocytes (IE) in the intervillous spaces of the placenta and is associated with foetal growth restriction and maternal anemia. IE accumulation is supported by the binding of the parasite-expressed protein VAR2CSA to placental chondroitin sulfate A (CSA). Defining specific CSA-binding epitopes of VAR2CSA, against which to target the immune response, is essential for the development of a vaccine aimed at blocking IE adhesion. However, the development of a VAR2CSA adhesion-blocking vaccine remains challenging due to (i) the large size of VAR2CSA and (ii) the extensive immune selection for polymorphisms and thereby non-neutralizing B-cell epitopes. Camelid heavy-chain-only antibodies (HcAbs) are known to target epitopes that are less immunogenic to classical IgG and, due to their small size and protruding antigen-binding loop, able to reach and recognize cryptic, conformational epitopes which are inaccessible to conventional antibodies. The variable heavy chain (VHH) domain is the antigen-binding site of camelid HcAbs, the so called Nanobody, which represents the smallest known (15 kDa) intact, native antigen-binding fragment. In this study, we have used the Nanobody technology, an approach new to malaria research, to generate small and functional antibody fragments recognizing unique epitopes broadly distributed on VAR2CSA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several nanobodies to DBL1 and ID1–ID2a reduced parasite adhesion to CSA while nanobodies to DBL4, DBL5 and DBL6 had no inhibitory activity [61,62].”
From Designing a VAR2CSA-based vaccine to prevent placental malaria (2015) · cites this paper as [61]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809 · cited 2×
“The CDR regions of Nbs are often longer and more flexible than corresponding regions of conventional antibodies and thus can bind epitopes that physically cannot be targeted by conventional immunoglobulins [28,31,32].”
Salanti, A., Staalsoe, T., Lavstsen, T., Jensen, A. T. R., Sowa, M. P. K., Arnot, D. E., Hviid, L., & Theander, T. G. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03570.x · Cited by 702
Self-citationEvidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria
Salanti, A., Dahlbäck, M., Turner, L., Nielsen, M. A., Barfod, L., Magistrado, P., Jensen, A. T. R., Lavstsen, T., Ofori, M. F., Marsh, K., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041579 · Cited by 604 · cited 1×
“During subsequent pregnancies, women build up protective immunity to placental malaria by acquiring antiVAR2CSA antibodies that prevent IE binding to CSA in the placenta [6,7].”
Self-citationSingle domain camel antibodies: current status
Muyldermans, S. (2001) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(01)00021-6 · Cited by 552 · cited 1×
“The variable heavy chain (VHH) domain is the antigen-binding site of camelid HcAbs and represents the smallest (15 kDa), intact, native antigenbinding fragment [23].”
Camelid immunoglobulins and nanobody technology
Muyldermans, S., Baral, T. N., Retamozzo, V. C., De Baetselier, P., De Genst, E., Kinne, J., Leonhardt, H., Magez, S., Nguyen, V. K., Revets, H., et al. (2009) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2008.10.299 · Cited by 533
Self-citationSingle domain antibodies: promising experimental and therapeutic tools in infection and immunity
Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juarez, K., Urrutia, M., Cauerhff, A., Danquah, W., Rissiek, B., Scheuplein, F., et al. (2009) · Medical Microbiology and Immunology · doi:10.1007/s00430-009-0116-7 · Cited by 513
Muyldermans, S., Atarhouch, T., Saldanha, J., Barbosa, J. A. R. G., & Hamers, R. (1994) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/7.9.1129 · Cited by 494 · cited 1×
“The CDR regions of Nbs are often longer and more flexible than corresponding regions of conventional antibodies and thus can bind epitopes that physically cannot be targeted by conventional immunoglobulins [28,31,32].”
The Sick Placenta—The Role of Malaria
Brabin, B. J., Romagosa, C., Abdelgalil, S., Menéndez, C., Verhoeff, F. H., McGready, R., Fletcher, K. A., Owens, S., d'Alessandro, U., Nosten, F., et al. (2004) · Placenta · doi:10.1016/j.placenta.2003.10.019 · Cited by 375 · cited 1×
“IE adhesion to the placenta triggers the recruitment and activation of maternal mononuclear cells secreting pro-inflammatory cytokines, leading to further inflammation and negative effects on placental function [4] and fetal development [5].”
β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae
Conrath, K. E., Lauwereys, M., Galleni, M., Matagne, A., Frère, J.-M., Kinne, J., Wyns, L., & Muyldermans, S. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2807-2812.2001 · Cited by 347 · cited 1×
“Construction of the Nanobody library and selection of VAR2CSA-specific Nanobodies The nanobody library was constructed as previously described by Conrath et al, 2001.”
MethodEfficient Targeting of Conserved Cryptic Epitopes of Infectious Agents by Single Domain Antibodies
Stijlemans, B., Conrath, K., Cortez-Retamozo, V., Van Xong, H., Wyns, L., Senter, P., Revets, H., De Baetselier, P., Muyldermans, S., & Magez, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307341200 · Cited by 276
Self-citation
Cited by
Xie, Y. J., Dougan, M., Jailkhani, N., Ingram, J., Fang, T., Kummer, L., Momin, N., Pishesha, N., Rickelt, S., Hynes, R. O., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817147116 · Cited by 296
Vasopressors for hypotensive shock
Gamper, G., Havel, C., Arrich, J., Losert, H., Pace, N. L., Müllner, M., & Herkner, H. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003709.pub4 · Cited by 239
Antigen recognition by single-domain antibodies: structural latitudes and constraints
Henry, K. A., & MacKenzie, C. R. (2018) · mAbs · doi:10.1080/19420862.2018.1489633 · Cited by 109
“Likewise, Ditlev et al.70 attributed the binding of a panel of alpaca VHHs to multiple domains of themalarial VAR2CSAprotein to an inherent ability of VHHs to recognize subdominant epitopes, although limited understanding of the human conventional antibody response against VAR2CSA as well as irreproducibility of these…”
BackgroundZhu, M., Gong, X., Hu, Y., Ou, W., & Wan, Y. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0352-5 · Cited by 96
“However, the conventional method is to subclone the VHH fragment from the phagemid into an expression plasmid [27].”
BackgroundMethodDesigning a VAR2CSA-based vaccine to prevent placental malaria
Fried, M., & Duffy, P. E. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.011 · Cited by 86
“Oleinikov et al. [42] reported significantly higher levels f antibodies to DBL1, DBL3 and DBL6 (but not DBL4 or DBL5) n multigravidae compared to primigravidae living in a malaria oloendemic area of Tanzania.”
BackgroundInfluentialResearch progress and applications of nanobody in human infectious diseases
Mei, Y., Chen, Y., Sivaccumar, J. P., An, Z., Xia, N., & Luo, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.963978 · Cited by 77
“These antibodies are expected to play an essential role in disease research, diagnosis and treatment in the future (Ditlev et al., 2014).”
BackgroundA nanobody modulates the p53 transcriptional program without perturbing its functional architecture
Bethuyne, J., De Gieter, S., Zwaenepoel, O., Garcia-Pino, A., Durinck, K., Verhelle, A., Hassanzadeh-Ghassabeh, G., Speleman, F., Loris, R., & Gettemans, J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku962 · Cited by 44
“oncology (10–13), parasitology (14,15), neuropathology (16) and immunology (17).”
BackgroundNanobodies: From High-Throughput Identification to Therapeutic Development
Fridy, P. C., Rout, M. P., & Ketaren, N. E. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100865 · Cited by 49
Generation of a Nanobody Targeting the Paraflagellar Rod Protein of Trypanosomes
Obishakin, E., Stijlemans, B., Santi‐Rocca, J., Vandenberghe, I. H. M., Devreese, B. V., Muldermans, S., Bastin, P., & Magez, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115893 · Cited by 33
“In addition, nanobody technology has been recently introduced as tools in malaria and cancer research [18, 19].”
Self-citationLi, M., Zhu, M., Zhang, C., Liu, X., & Wan, Y. (2014) · Toxins · doi:10.3390/toxins6123208 · Cited by 31
“coli WK6 electrocompetent cells respectively from TG1 strain by conventional method [27].”
BackgroundMethodImproving the yield of recalcitrant Nanobodies® by simple modifications to the standard protocol
Kariuki, C. K., & Magez, S. (2021) · Protein Expression and Purification · doi:10.1016/j.pep.2021.105906 · Cited by 29
Self-citationGangnard, S., Lewit-Bentley, A., Dechavanne, S., Srivastava, A., Amirat, F., Bentley, G. A., & Gamain, B. (2015) · Scientific Reports · doi:10.1038/srep14868 · Cited by 25
Qaraghuli, M. M. A., & Ferro, V. A. (2016) · Journal of Molecular Recognition · doi:10.1002/jmr.2592 · Cited by 31
“CDRs of the VHH and VNAR domains were determined following standard definitions.(28,39,66,67) MSA and SASA were calculated in square angstrom (Å(2)) using PyMOL (academic ver-”
MethodStrategy exploration for developing robust lyophilized cell-free systems
Yang, J., Cui, Y., Cao, Z., Ma, S., & Lu, Y. (2021) · Biotechnology Notes · doi:10.1016/j.biotno.2021.08.004 · Cited by 23
The statistical importance of a study for a network meta-analysis estimate
Rücker, G., Nikolakopoulou, A., Papakonstantinou, T., Salanti, G., Riley, R. D., & Schwarzer, G. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-01075-y · Cited by 24
Nunes-Silva, S., Gangnard, S., Vidal, M., Vuchelen, A., Dechavanne, S., Chan, S., Pardon, E., Steyaert, J., Ramboarina, S., Chêne, A., et al. (2014) · Scientific Reports · doi:10.1038/srep07373 · Cited by 15
Bertier, L., Hebbrecht, T., Mettepenningen, E., Wit, N. D., Zwaenepoel, O., Verhelle, A., & Gettemans, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.064 · Cited by 15
Structural insights into a high affinity nanobody:antigen complex by homology modelling
Skottrup, P. D. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2017.07.008 · Cited by 15
Andersson, A.-M. C., Resende, M., Salanti, A., Nielsen, M. A., & Holst, P. J. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.01.016 · Cited by 14
Self-citationCryptic epitope for antibodies should not be forgotten in vaccine design
Good, M. F., & Yanow, S. K. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1154791 · Cited by 9
“Camelid ‘nanobodies’ were used to define epitopes on a malaria-target antigen [16] and IgNARs (‘immunoglobulin new antigen receptors’ – from cartilaginous fishes) were used to probe a hydrophobic cleft on another malaria protein which may lead to a novel vaccine candidate or small molecule inhibitor [17].”
MethodBrito, C., & Vieira, N. (2016) · Springer eBooks · doi:10.1007/978-94-017-7496-3_10 · Cited by 8
Lee, C., Kang, Y., Ho, C., Lin, C. S., Chen, P., Wu, Y., & Huang, T. (2020) · Medicine · doi:10.1097/md.0000000000019618 · Cited by 7
Chemical Biology Tools To Investigate Malaria Parasites
Broichhagen, J., & Kilian, N. (2021) · ChemBioChem · doi:10.1002/cbic.202000882 · Cited by 7
Schaden, L.-M., Wimmer‐Teubenbacher, M., Poms, J., Laggner, P., Lohner, K., Sacher, S., Khinast, J., & Salar-Behzadi, S. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2417-2 · Cited by 6
Intrabody-Induced Cell Death by Targeting the T. brucei Cytoskeletal Protein Tb BILBO1
Reix, C. E. B., Ramanantsalama, M. R., Primo, C. D., Minder, L., Bonhivers, M., Dacheux, D., & Robinson, D. R. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00915-21 · Cited by 6
“transfected, extracted U-2 OS cells were probed with anti-TbBILBO1 (1-110) and Nb48::HA::6His, and 354 showed a negative signal (Figure 8A).”
InfluentialXiong, C., Li, Y., Zeng, Y., Wei, H., Zhuang, G., Li, L., Zhao, L.-H., Li, C., Qin, E., & Fu, J. (2019) · Medicine · doi:10.1097/md.0000000000017002 · Cited by 4
Álvarez-Rodríguez, A., Radwanska, M., Magez, S., & Odongo, S. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1001065 · Cited by 2
Self-citationAnfossi, L. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.104177 · Cited by 2
Nanobody MET CAR-T cells show efficacy in solid tumorsPreprint
Chen, P., Li, Q., Deveraux, S., Sohai, D. K., Cha, P., Raghunandan, R., Chen, N., Li, Y., Nguyen, M. T., Stankewich, M. C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.27.702111
“Given the aggressive nature of tumors generally associated with MET overexpression, these findings indicate that VHH2-CAR-T could efficiently control tumor growth by eliminating MET-positive tumor cells.”
Camelid Single-Domain Antibodies as Tools for Novel Target Identification in Kinetoplastid Research
Odongo, S., Vocht, L. D., Jin, B.-K., Li, Z., Magez, S., & Sterckx, Y. G. ‐. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5146-9_22
Self-citationCalderoni, A., Nannoni, M., Ruffini, G., Doglio, M., Bercher-Brayer, C., Giannelli, S. G., Melki, R., Casucci, M., Bonini, C., Muggeo, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.21.746338
Metadata
- Authors
- Ditlev, S. B., Florea, R., Nielsen, M. A., Theander, T. G., Magez, S., Boeuf, P., & Salanti, A.
- Affiliations
- University of Copenhagen (DK)
- Vrije Universiteit Brussel (BE)
- The Royal Melbourne Hospital (AU)
- Corresponding author
- Ditlev, Sisse B.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-01-21
- Volume
- 9
- Issue
- 1
- Pages
- e84981
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3897377
- OpenAlex
- W2043051805
- Cited by
- 31
- References
- 37
- Citations by year
- 2026: 3 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 5
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Højteknologifonden
- Agentschap voor Innovatie door Wetenschap en Technologie
- Novo Nordisk
- Novo Nordisk Fonden
- National Health and Medical Research Council (1003384)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Keywords
- VAR2CSA, placental malaria, Plasmodium falciparum, chondroitin sulfate A, nanobodies, VHH, heavy-chain antibodies, epitope mapping, infected erythrocyte adhesion, placenta, conformational epitopes
- MeSH terms
- Amino Acid Sequence, Animals, Epitopes, Antigens, Protozoan, Camelids, New World, Chondroitin Sulfates, Erythrocytes, Humans, Immunoglobulin Heavy Chains, Molecular Sequence Data, Plasmodium falciparum, Protein Binding, Recombinant Proteins, Sequence Alignment, Malaria, Falciparum, Peptide Library, Single-Domain Antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.